Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation

• DOI: 10.1038/leu.2014.314
• Publication Date: 2014-11-05T07:45:29Z
• Authors: L Crucitti; R Crocchiolo; C Toffalori; B Mazzi; R Greco; A Signori; F Sizzano; L Chiesa; E Zino; M T Lupo Stanghel...; A Assanelli; M G Carrabba; S Marktel; M Marcatti; C Bordignon; C Corti; M Bernardi; J Peccatori; C Bonini; K Fleischhauer; F Ciceri; L Vago
• Keywords: Adult; Male; 0303 health sciences; Adolescent; Histocompatibility Testing; Incidence; Medizin; Hematopoietic Stem Cell Transplantation; Graft vs Host Disease; leukemia; HLA; hematopoietic stem cell transplantation; Middle Aged; 3. Good health; Leukemia, Myeloid, Acute; Young Adult; 03 medical and health sciences; HLA Antigens; Recurrence; Risk Factors; Mutation; Humans; Female; Aged; Proportional Hazards Models; Retrospective Studies

Genomic loss of the mismatched human leukocyte antigen (HLA) is a recently described mechanism of leukemia immune escape and relapse after allogeneic hematopoietic stem cell transplantation (HSCT). Here we first evaluated its incidence, risk factors and outcome in 233 consecutive transplants from partially HLA-mismatched related and unrelated donors (MMRD and MMUD, respectively). We documented 84 relapses, 23 of which with HLA loss. All the HLA loss relapses occurred after MMRD HSCT, and 20/23 in patients with acute myeloid leukemia. Upon MMRD HSCT, HLA loss variants accounted for 33% of the relapses (23/69), occurring later than their 'classical' counterparts (median: 307 vs 88 days, P<0.0001). Active disease at HSCT increased the risk of HLA loss (hazard ratio (HR): 10.16; confidence interval (CI): 2.65-38.92; P=0.001), whereas older patient ages had a protective role (HR: 0.16; CI: 0.05-0.46; P=0.001). A weaker association with HLA loss was observed for graft T-cell dose and occurrence of chronic graft-versus-host disease. Outcome after 'classical' and HLA loss relapses was similarly poor, and second transplantation from a different donor appeared to provide a slight advantage for survival. In conclusion, HLA loss is a frequent mechanism of evasion from T-cell alloreactivity and relapse in patients with myeloid malignancies transplanted from MMRDs, warranting routine screening in this transplantation setting.